Journal of Medical Ethics · 2012 · 25 citations · 11 references
Life SciencesGeneticsPharmacoeconomicsHealth EquityMedical EthicsMedical GeneticsEthnicity In HealthGenetic DisordersIndigenous HealthLysosomal Storage DisordersRare Disease GeneticsEnzyme Replacement TherapyHealth Care EconomicsIndigenous Medical EthicsIndigenous Minorities
Mucopolysaccharidosis VI is an autosomal recessive lysosomal storage disorder associated with severe disability and premature death. The presence of a mucopolysaccharidosis-like disease in indigenous ethnic groups in Colombia can be inferred from archaeological findings. There are several indigenous patients with mucopolysaccharidosis VI currently receiving enzyme replacement therapy. We discuss the ethical and economic considerations, regarding both direct and indirect costs, of a high-cost orphan disease in a marginalised minority population in a developing country.
11
Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · The Journal of Pediatrics · 2006 · 364 citations
Tay-Sachs Disease— Carrier Screening, Prenatal Diagnosis, and the Molecular Era
Michael M. Kaback · JAMA · 1993 · 257 citations
Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence
Gunilla Malm, Allan M. Lund, Jan‐Eric Månsson et al. · Acta Paediatrica · 2008 · 123 citations
Medicine, Pathology, Pediatrics +8
Paul Harmatz, Zi‐Fan Yu, Roberto Giugliani et al. · Journal of Inherited Metabolic Disease · 2010 · 92 citations · Full text
Health Professions, Pharmacotherapy, Clinical Biochemistry +10